We Tested BPC-157 From 12 Companies. Here’s What We Found.

BPC-157 is the most requested compound we track and one of the least supported by human evidence. It is sold as a research chemical by a large fraction of the companies in The Peptide Index™, marketed for tendon, ligament and gut healing, and studied almost entirely in rodents. That gap, enormous commercial demand sitting on top of a thin evidence base, is exactly the condition in which product quality tends to drift, because very few buyers are in a position to check.

So we checked. Over the past two years the Institute has purchased and independently tested 23 BPC-157 samples from 12 different sellers, using anonymous retail orders shipped to unaffiliated addresses. Every sample went to a contract laboratory under chain-of-custody documentation for reversed-phase HPLC purity analysis and mass-spectrometry identity confirmation, with quantitative content analysis where the product carried a milligram claim.

The headline finding is that most BPC-157 on the market is roughly what it says it is, and a meaningful minority is not. 19 of 23 samples, 83%, met their label claims on both purity and content. That leaves 4 that did not: 2 with measurable discrepancies against the label and 2 that failed verification outright.

The spread is the part worth sitting with. Measured purity across the cohort ran from 61% to 98.9%, against a claim that is almost universally stated as "≥98%" or "99%+". Two vials of nominally identical product, bought in the same month from two companies with similar-looking websites, can differ by 37.9 percentage points of actual compound. Nothing on either label would tell a buyer which one they had.

Company identity turns out to predict this better than price does. Apex Peptides averaged 97.4% across 3 samples with no failures or discrepancies. At the other end, Cascade Research Group averaged 74.2%, with a single-sample low of 61%. Both sell the same compound at broadly comparable prices.

We want to be precise about what this does and does not establish. It does not tell you that BPC-157 works, the human evidence for that remains thin, and nothing in a purity assay speaks to efficacy. It tells you that if you have decided to obtain it, the seller you choose materially changes what ends up in the vial, and that the difference is measurable, consistent, and invisible from the product page.

Every specimen in this investigation is published in full in our testing database, including the chromatograms, the laboratory that ran each assay, the lot number and the purchase date. Companies were notified before publication and given our standard dispute window. Where a sample failed, we purchased and tested a second sample from a separate lot at a different laboratory before publishing anything.